CA2856424A1 - A method to enhance cognition - Google Patents
A method to enhance cognition Download PDFInfo
- Publication number
- CA2856424A1 CA2856424A1 CA2856424A CA2856424A CA2856424A1 CA 2856424 A1 CA2856424 A1 CA 2856424A1 CA 2856424 A CA2856424 A CA 2856424A CA 2856424 A CA2856424 A CA 2856424A CA 2856424 A1 CA2856424 A1 CA 2856424A1
- Authority
- CA
- Canada
- Prior art keywords
- pkr
- mice
- pkri
- slices
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564371P | 2011-11-29 | 2011-11-29 | |
| US61/564,371 | 2011-11-29 | ||
| PCT/US2012/067078 WO2013082292A1 (en) | 2011-11-29 | 2012-11-29 | A method to enhance cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2856424A1 true CA2856424A1 (en) | 2013-06-06 |
Family
ID=48536059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856424A Abandoned CA2856424A1 (en) | 2011-11-29 | 2012-11-29 | A method to enhance cognition |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140336184A1 (enExample) |
| EP (1) | EP2785377A4 (enExample) |
| JP (1) | JP2015500805A (enExample) |
| CN (1) | CN104039353A (enExample) |
| AU (1) | AU2012345888A1 (enExample) |
| CA (1) | CA2856424A1 (enExample) |
| HK (1) | HK1200085A1 (enExample) |
| WO (1) | WO2013082292A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107969126A (zh) * | 2015-06-26 | 2018-04-27 | 埃克西金炎症有限公司 | Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途 |
| DK3383482T3 (da) | 2015-11-24 | 2023-04-11 | Massachusetts Inst Technology | Systemer og fremgangsmåder til forebyggelse, mildnelse og/eller behandling af demens |
| US10279192B2 (en) | 2016-11-17 | 2019-05-07 | Cognito Therapeutics, Inc. | Methods and systems for neural stimulation via visual stimulation |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
| WO2019074637A1 (en) | 2017-10-10 | 2019-04-18 | Massachusetts Institute Of Technology | SYSTEMS AND METHODS FOR PREVENTION, MITIGATION AND / OR TREATMENT OF DEMENTIA |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153634A (en) * | 1998-12-17 | 2000-11-28 | Hoffmann-La Roche Inc. | 4,5-azolo-oxindoles |
| US20040127471A1 (en) * | 2002-09-17 | 2004-07-01 | Barry Reisberg | Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors |
| WO2006114019A1 (en) * | 2005-04-26 | 2006-11-02 | Versitech Limited | Polysaccharide extract from lycium barbarum as neuroprotective agent against beta-amyloid peptide neurotoxicity |
| CA2706656A1 (en) * | 2007-11-26 | 2009-06-04 | Nestec S.A. | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| EP2381934A2 (en) * | 2008-12-23 | 2011-11-02 | Carmel - Haifa University Economic Corp Ltd. | Improving cognitive function |
| SG179163A1 (en) * | 2009-09-16 | 2012-05-30 | Cylene Pharmaceuticals Inc | Novel tricyclic protein kinase modulators |
-
2012
- 2012-11-29 AU AU2012345888A patent/AU2012345888A1/en not_active Abandoned
- 2012-11-29 JP JP2014544885A patent/JP2015500805A/ja active Pending
- 2012-11-29 CN CN201280058641.1A patent/CN104039353A/zh active Pending
- 2012-11-29 EP EP12853597.8A patent/EP2785377A4/en not_active Withdrawn
- 2012-11-29 CA CA2856424A patent/CA2856424A1/en not_active Abandoned
- 2012-11-29 US US14/361,223 patent/US20140336184A1/en not_active Abandoned
- 2012-11-29 HK HK14112659.1A patent/HK1200085A1/xx unknown
- 2012-11-29 WO PCT/US2012/067078 patent/WO2013082292A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HK1200085A1 (en) | 2015-07-31 |
| EP2785377A4 (en) | 2015-07-08 |
| AU2012345888A1 (en) | 2014-05-29 |
| CN104039353A (zh) | 2014-09-10 |
| JP2015500805A (ja) | 2015-01-08 |
| EP2785377A1 (en) | 2014-10-08 |
| WO2013082292A1 (en) | 2013-06-06 |
| US20140336184A1 (en) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7802514B2 (ja) | 新規メチルキナゾリノン誘導体 | |
| US10548892B2 (en) | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | |
| EP2609082B1 (de) | Imidazo[4,5-c]chinoline als dna-pk-inhibitoren | |
| BR112021003039A2 (pt) | combinações para o tratamento de nash/nafld e doenças relacionadas | |
| BRPI0621027A2 (pt) | composto, composição farmacêutica | |
| CN102844023A (zh) | Cdc7激酶抑制剂以及其用途 | |
| TR201802280T4 (tr) | İnsan protein tirosin fosfataz inhibitörleri ve bunların farmasötik kullanımları. | |
| WO2018053373A1 (en) | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis | |
| US20140336184A1 (en) | Method to enhance cognition | |
| SK154796A3 (en) | Use of rapamycin for the inhibition of neuronal cells necrosis | |
| BR112017000730B1 (pt) | Derivados de pirrolidinona como inibidores de metap-2 | |
| BR112019018843A2 (pt) | composto, processo para preparar compostos, composição farmacêutica, combinação, processo para fabricação de uma composição farmacêutica, e, método de tratamento e/ou prevenção de um distúrbio | |
| EP4308097A1 (en) | Non-hydroxamate hdac6 inhibitors and related methods of use | |
| BR112021014466A2 (pt) | Derivados de indazolil-isoxazol para o tratamento de doenças, tal como câncer | |
| RU2339620C1 (ru) | Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции | |
| EP3664806B1 (en) | 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS | |
| US20190105341A1 (en) | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | |
| US10487045B2 (en) | Adamantane derivative and use thereof | |
| EP2522394B1 (en) | Substituted phosphonates and their use decreasing amyloid aggregates | |
| EP0667349A1 (en) | Depression remedy | |
| WO2022192252A1 (en) | Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway | |
| US12139505B2 (en) | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | |
| US20250388571A1 (en) | Amp-activated protein kinase modulator compounds and uses thereof | |
| JP2021529782A (ja) | 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法 | |
| WO2014127112A1 (en) | Memory enhancer and actin dynamics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181129 |